Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.


Journal

The Lancet. Oncology
ISSN: 1474-5488
Titre abrégé: Lancet Oncol
Pays: England
ID NLM: 100957246

Informations de publication

Date de publication:
05 2020
Historique:
received: 03 12 2019
revised: 20 01 2020
accepted: 22 01 2020
pubmed: 1 4 2020
medline: 10 7 2020
entrez: 1 4 2020
Statut: ppublish

Résumé

Few options exist for treatment of patients with small-cell lung cancer (SCLC) after failure of first-line therapy. Lurbinectedin is a selective inhibitor of oncogenic transcription. In this phase 2 study, we evaluated the acti and safety of lurbinectedin in patients with SCLC after failure of platinum-based chemotherapy. In this single-arm, open-label, phase 2 basket trial, we recruited patients from 26 hospitals in six European countries and the USA. Adults (aged ≥18 years) with a pathologically proven diagnosis of SCLC, Eastern Cooperative Oncology Group performance status of 2 or lower, measurable disease as per Response Criteria in Solid Tumors (RECIST) version 1.1, absence of brain metastasis, adequate organ function, and pre-treated with only one previous chemotherapy-containing line of treatment (minimum 3 weeks before study initiation) were eligible. Treatment consisted of 3·2 mg/m Between Oct 16, 2015, and Jan 15, 2019, 105 patients were enrolled and treated with lurbinectedin. Median follow-up was 17·1 months (IQR 6·5-25·3). Overall response by investigator assessment was seen in 37 patients (35·2%; 95% CI 26·2-45·2). The most common grade 3-4 adverse events (irrespective of causality) were haematological abnormalities-namely, anaemia (in nine [9%] patients), leucopenia (30 [29%]), neutropenia (48 [46%]), and thrombocytopenia (seven [7%]). Serious treatment-related adverse events occurred in 11 (10%) patients, of which neutropenia and febrile neutropenia were the most common (five [5%] patients for each). No treatment-related deaths were reported. Lurbinectedin was active as second-line therapy for SCLC in terms of overall response and had an acceptable and manageable safety profile. Lurbinectedin could represent a potential new treatment for patients with SCLC, who have few options especially in the event of a relapse, and is being investigated in combination with doxorubicin as second-line therapy in a randomised phase 3 trial. Pharma Mar.

Sections du résumé

BACKGROUND
Few options exist for treatment of patients with small-cell lung cancer (SCLC) after failure of first-line therapy. Lurbinectedin is a selective inhibitor of oncogenic transcription. In this phase 2 study, we evaluated the acti and safety of lurbinectedin in patients with SCLC after failure of platinum-based chemotherapy.
METHODS
In this single-arm, open-label, phase 2 basket trial, we recruited patients from 26 hospitals in six European countries and the USA. Adults (aged ≥18 years) with a pathologically proven diagnosis of SCLC, Eastern Cooperative Oncology Group performance status of 2 or lower, measurable disease as per Response Criteria in Solid Tumors (RECIST) version 1.1, absence of brain metastasis, adequate organ function, and pre-treated with only one previous chemotherapy-containing line of treatment (minimum 3 weeks before study initiation) were eligible. Treatment consisted of 3·2 mg/m
FINDINGS
Between Oct 16, 2015, and Jan 15, 2019, 105 patients were enrolled and treated with lurbinectedin. Median follow-up was 17·1 months (IQR 6·5-25·3). Overall response by investigator assessment was seen in 37 patients (35·2%; 95% CI 26·2-45·2). The most common grade 3-4 adverse events (irrespective of causality) were haematological abnormalities-namely, anaemia (in nine [9%] patients), leucopenia (30 [29%]), neutropenia (48 [46%]), and thrombocytopenia (seven [7%]). Serious treatment-related adverse events occurred in 11 (10%) patients, of which neutropenia and febrile neutropenia were the most common (five [5%] patients for each). No treatment-related deaths were reported.
INTERPRETATION
Lurbinectedin was active as second-line therapy for SCLC in terms of overall response and had an acceptable and manageable safety profile. Lurbinectedin could represent a potential new treatment for patients with SCLC, who have few options especially in the event of a relapse, and is being investigated in combination with doxorubicin as second-line therapy in a randomised phase 3 trial.
FUNDING
Pharma Mar.

Identifiants

pubmed: 32224306
pii: S1470-2045(20)30068-1
doi: 10.1016/S1470-2045(20)30068-1
pii:
doi:

Substances chimiques

Carbolines 0
Heterocyclic Compounds, 4 or More Rings 0
PM 01183 0
Doxorubicin 80168379AG

Banques de données

ClinicalTrials.gov
['NCT02454972']

Types de publication

Clinical Trial, Phase II Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

645-654

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

José Trigo (J)

Hospital Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga, Málaga, Spain. Electronic address: jmtrigo@seom.org.

Vivek Subbiah (V)

MD Anderson Cancer Center, Houston, TX, USA.

Benjamin Besse (B)

Gustave Roussy Cancer Campus, Villejuif, France; Paris Sud University, Orsay, France.

Victor Moreno (V)

START Madrid-Fundación Jiménez Díaz, Hospital Fundación Jiménez Díaz, Madrid, Spain.

Rafael López (R)

Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.

María Angeles Sala (MA)

Organización Sanitaria Integrada Bilbao Basurto, Bilbao, Spain.

Solange Peters (S)

University Hospital Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Santiago Ponce (S)

Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Unit, Universidad Complutense de Madrid, Madrid, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain.

Cristian Fernández (C)

Pharma Mar, Clinical Research and Development, Colmenar Viejo, Madrid, Spain.

Vicente Alfaro (V)

Pharma Mar, Clinical Research and Development, Colmenar Viejo, Madrid, Spain.

Javier Gómez (J)

Pharma Mar, Clinical Research and Development, Colmenar Viejo, Madrid, Spain.

Carmen Kahatt (C)

Pharma Mar, Clinical Research and Development, Colmenar Viejo, Madrid, Spain.

Ali Zeaiter (A)

Pharma Mar, Clinical Research and Development, Colmenar Viejo, Madrid, Spain.

Khalil Zaman (K)

University Hospital Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Valentina Boni (V)

START Madrid-Centro Integral Oncológico Clara Campal, Hospital Universitario Sanchinarro, Madrid, Spain.

Jennifer Arrondeau (J)

Hôpital Cochin, Paris, France.

Maite Martínez (M)

Complejo Hospitalario de Navarra, Pamplona, Spain.

Jean-Pierre Delord (JP)

Institut Claudius Regaud, Toulouse, France.

Ahmad Awada (A)

Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

Rebecca Kristeleit (R)

University College London Cancer Institute, London, UK.

Maria Eugenia Olmedo (ME)

Hospital Universitario Ramón y Cajal, Madrid, Spain.

Luciano Wannesson (L)

Ospedale San Giovanni, Bellinzona, Switzerland.

Javier Valdivia (J)

Hospital Universitario Virgen de las Nieves, Granada, Spain.

María Jesús Rubio (MJ)

Hospital Universitario Reina Sofía, Cordoba, Spain.

Antonio Anton (A)

Hospital Universitario Miguel Servet, Zaragoza, Spain.

John Sarantopoulos (J)

Institute for Drug Development, Mays Cancer Center at University of Texas Health San Antonio, MD Anderson Cancer Center, San Antonio, TX, USA.

Sant P Chawla (SP)

Sarcoma Oncology Center, Santa Monica, CA, USA.

Joaquín Mosquera-Martinez (J)

Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.

Manolo D'Arcangelo (M)

Ospedale Santa Maria delle Croci, Ravenna, Italy.

Armando Santoro (A)

Humanitas Clinical and Research Center - IRCCS, Humanitas Cancer Center, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

Victor M Villalobos (VM)

University of Colorado Cancer Center, Aurora, CO, USA.

Jacob Sands (J)

Dana-Farber Cancer Institute, Boston, MA, USA.

Luis Paz-Ares (L)

Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Unit, Universidad Complutense de Madrid, Madrid, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH